Principal Financial Group Inc. Has $85,000 Stock Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Principal Financial Group Inc. lessened its stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 50.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 11,641 shares of the biotechnology company’s stock after selling 11,951 shares during the period. Principal Financial Group Inc.’s holdings in Aurinia Pharmaceuticals were worth $85,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of AUPH. Banque Cantonale Vaudoise boosted its stake in Aurinia Pharmaceuticals by 126.6% in the 2nd quarter. Banque Cantonale Vaudoise now owns 9,684 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 5,410 shares during the period. CWM LLC grew its holdings in shares of Aurinia Pharmaceuticals by 247.7% during the third quarter. CWM LLC now owns 11,483 shares of the biotechnology company’s stock valued at $84,000 after buying an additional 8,180 shares in the last quarter. B. Riley Wealth Advisors Inc. acquired a new position in Aurinia Pharmaceuticals during the second quarter valued at $84,000. Virtu Financial LLC purchased a new stake in Aurinia Pharmaceuticals in the 1st quarter worth about $78,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in Aurinia Pharmaceuticals by 63.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 27,502 shares of the biotechnology company’s stock worth $202,000 after acquiring an additional 10,700 shares during the period. Institutional investors and hedge funds own 36.83% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $13.00 target price on shares of Aurinia Pharmaceuticals in a report on Friday, September 6th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $10.00 price objective on shares of Aurinia Pharmaceuticals in a research note on Monday, September 16th. Finally, StockNews.com raised shares of Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 8th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $10.00.

Aurinia Pharmaceuticals Price Performance

Shares of NASDAQ:AUPH opened at $8.71 on Wednesday. The stock has a market capitalization of $1.25 billion, a P/E ratio of -58.07 and a beta of 1.45. The business has a 50-day moving average of $7.50 and a two-hundred day moving average of $6.41. Aurinia Pharmaceuticals Inc. has a fifty-two week low of $4.71 and a fifty-two week high of $9.74. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11.

Insider Activity at Aurinia Pharmaceuticals

In related news, Director Jeffrey Allen Bailey sold 4,557 shares of the company’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $8.43, for a total transaction of $38,415.51. Following the completion of the sale, the director now directly owns 13,356 shares of the company’s stock, valued at approximately $112,591.08. This represents a 25.44 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.30% of the stock is owned by company insiders.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.